BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-25 out of 210 found
  Current Search:  copaxone: 210     

HTML
100%
Teva buys rival Ratiopharm
ISRAELs Teva Pharmaceutical Industries won the battle for German generic drug maker Ratiopharm, paying an enterprise value of 3,625bn to fix the industry leaders weakness in the worlds second-largest generics market.

Tevas bid, which beat US drugs leader...

Business Day:  Mar 19 2010 6:07AM
Matching: copaxone
Find similar documents
HTML
100%
Teva In $5B Deal To Buy Ratiopharm
FRANKFURT -- Israeli drug maker Teva has beaten out rivals Pfizer and Actavis to acquire German generic drug maker Ratiopharm GmbH - in a deal announced Thursday worth some euro3.6 billion, or nearly $5 billion.

The deal, which is being paid for with cash and...

Forbes.com:  Mar 18 2010 10:10PM
Matching: copaxone
Find similar documents
HTML
100%
Teva to buy German generic drug maker Ratiopharm
FRANKFURT (AP) Israeli drug maker Teva has beaten out rivals Pfizer and Actavis to acquire German generic drug maker Ratiopharm GmbH in a deal announced Thursday worth some euro3.6 billion, or nearly $5 billion.

Teva Pharmaceutical Industries Ltd.'s...

KTVQ.com:  Mar 18 2010 7:50PM
Matching: copaxone
Find similar documents
HTML
100%
Teva to buy German generic drug maker Ratiopharm
FRANKFURT (AP) -- Israeli drug maker Teva has beaten out rivals Pfizer and Actavis to acquire German generic drug maker Ratiopharm GmbH - in a deal announced Thursday worth some euro3.6 billion, or nearly $5 billion.

Teva Pharmaceutical Industries Ltd.'s...

Northern Virginia Daily:  Mar 18 2010 7:40PM
Matching: copaxone
Find similar documents
HTML
100%
Teva to buy Ratiopharm for nearly $5 billion
Teva, which beat US drugs powerhouse Pfizer and Iceland's Actavis in the race for Ratiopharm, said the combined company would have had 2009 revenues of $16.2 billion, up from Teba's own sales of $13.9 billion.

Put on the auction block by Germany's Merckle...

Budapest Business Journal:  Mar 18 2010 6:33PM
Matching: copaxone
Find similar documents
HTML
100%
Teva to buy German generic drug maker Ratiopharm
FRANKFURT Israeli drug maker Teva has beaten out rivals Pfizer and Actavis to acquire German generic drug maker Ratiopharm GmbH in a deal announced Thursday worth some euro3.6 billion, or nearly $5 billion.

Teva Pharmaceutical Industries Ltd.'s successful bid...

Yahoo! News:  Mar 18 2010 3:33PM
Matching: copaxone
Find similar documents
HTML
100%
Teva to buy German generic drug maker Ratiopharm
FRANKFURT (AP) -- Israeli drug maker Teva has beaten out rivals Pfizer and Actavis to acquire German generic drug maker Ratiopharm GmbH - in a deal announced Thursday worth some euro3.6 billion, or nearly $5 billion.

Teva Pharmaceutical Industries Ltd.'s...

Associated Press:  Mar 18 2010 3:04PM
Matching: copaxone
Find similar documents
HTML
100%
It's a very good fit for Teva, and the market will view it positively
Teva, which beat U.S.

drugs powerhouse Pfizer (PFE.N Put on the auction block by Germany's Merckle family as its business empire crumbled, Ratiopharm vies with Stada (STAGn.

DE None of the other companies have yet commented on the deal.

Trade in Teva...

Reuters UK:  Mar 18 2010 2:55PM
Matching: copaxone
Find similar documents
HTML
100%
Teva buys Ratiopharm
Israeli drug maker Teva, number four in Germany's generics market, will jump straight to the top spot acquisition Email Please enter a valid e-mail address Please enter a comma delimited list of valid e-mail addresses Other ways of sharing: License this story...
Globe and Mail:  Mar 18 2010 1:54PM
Matching: copaxone
Find similar documents
HTML
100%
Teva Provides Update on Generic Temodar
Teva's Safe Harbor Statement under the U.

Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management.

Such statements are based on management's current...

Rock Hill Herald:  Mar 17 2010 1:44PM
Matching: copaxone
Find similar documents
HTML
100%
Teva Provides Update on Generic Temodar
Teva's Safe Harbor Statement under the U.

Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management.

Such statements are based on management's current...

Rock Hill Herald:  Mar 17 2010 1:43PM
Matching: copaxone
Find similar documents
HTML
100%
Teva to launch Laquinimod lupus clinical trial: The firm's new Multiple Sclerosis drug may be able to treat other illnesses as w
In the next few weeks Teva will begin recruiting patients for a Phase IIa clinical trial for Laquinimod for treating lupus nephritis, which affects the kidneys, and lupus arthritis, which affects joints.

The trial is slated to begin in the summer.

Teva has...

TradingMarkets:  Mar 16 2010 9:10PM
Matching: copaxone
Find similar documents
HTML
100%
Some with MS already use estriol - if they can get it [The Philadelphia Inquirer]
12--An untold number of women with multiple sclerosis are not waiting to see if estriol wins approval as a therapy before using it.

But these days, getting a prescription for the decades-old generic drug can be an ordeal.

Estriol's innocuousness -- no shots...

Therapeutics Daily:  Mar 12 2010 11:20AM
Matching: copaxone
Find similar documents
HTML
100%
5-Star Stocks Poised to Pop: Teva Pharmaceutical
Based on the aggregated intelligence of 150,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, generic drug specialist Teva Pharmaceutical Industries (Nasdaq: TEVA) has earned a coveted five-star ranking.

With that in...

Cafepharma:  Mar 11 2010 7:09AM
Matching: copaxone
Find similar documents
HTML
100%
Teva Pharmaceutical Industries Ltd. Announces new Chairman to its Board of Directors.
Generic Drug maker, Teva Pharmaceutical Industries Ltd.

(NASDAQ:TEVA) says it has chosen Vice Chairman, Dr.

Phillip Frost to serve as Chairman.

North Bergen, New Jersey 3/09/2010 04:43 PM GMT (TransWorldNews) Teva Pharmaceutical Industries Ltd.(NASDAQ...

TransWorldNews:  Mar 9 2010 5:15PM
Matching: copaxone
Find similar documents
HTML
100%
Israel's TEVA a Headache for Drug Firms, Rx for Investors
Follow Israel news on and.

(IsraelNN.com) Israel-based Teva Pharmaceuticals, besides making generic drugs, has made lots of people millionaires.

Sixteen years ago, its stock was worth $3.02 a share.

This week, it is trading at a new record high of...

Israel National News:  Mar 8 2010 2:09AM
Matching: copaxone
Find similar documents
HTML
100%
Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Scleros
CAMBRIDGE, Mass., March 5 /PRNewswire/ -- Peptimmune, Inc.

a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the escape_start39;221 patent) which protects the target product profile for its PI-2301 peptide...

TickerTech.com:  Mar 7 2010 1:40PM
Matching: copaxone
Find similar documents
HTML
100%
Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Scleros
CAMBRIDGE, Mass., March 5 /PRNewswire/ -- Peptimmune, Inc.

a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the escape_start39;221 patent) which protects the target product profile for its PI-2301 peptide...

KSLA:  Mar 6 2010 8:49PM
Matching: copaxone
Find similar documents
HTML
100%
Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
Peptimmune, Inc.

a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other...

Los Angeles Business:  Mar 6 2010 11:40AM
Matching: copaxone
Find similar documents
HTML
100%
Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Scleros
CAMBRIDGE, Mass., March 5 /PRNewswire/ -- Peptimmune, Inc.

a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the escape_start39;221 patent) which protects the target product profile for its PI-2301 peptide...

KOTA Territory News:  Mar 6 2010 10:41AM
Matching: copaxone
Find similar documents
HTML
100%
Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis
Peptimmune, Inc.

a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other...

News-Medical.Net:  Mar 6 2010 6:55AM
Matching: copaxone
Find similar documents
HTML
100%
Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
CAMBRIDGE, Mass., March 5 /PRNewswire/ -- Peptimmune, Inc.

a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the...

NewsBlaze:  Mar 6 2010 3:27AM
Matching: copaxone
Find similar documents
HTML
100%
Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
Peptimmune, Inc.

a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other...

Houston Business Journal:  Mar 6 2010 1:19AM
Matching: copaxone
Find similar documents
HTML
100%
Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
Peptimmune, Inc.

a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other...

Denver Business Journal:  Mar 6 2010 1:10AM
Matching: copaxone
Find similar documents
HTML
100%
Peptimmune Announces Second Grant of a United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
Peptimmune, Inc.

a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other...

Columbus Business First:  Mar 6 2010 12:50AM
Matching: copaxone
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.